New hope for women with resistant ovarian cancer: drug combo trial launches

NCT ID NCT05551507

First seen May 15, 2026 · Last updated May 15, 2026

Summary

This study tests a new drug called IN10018 combined with standard chemotherapy for women with a type of ovarian cancer that no longer responds to platinum-based treatments. About 150 adults will take part to see if the combination is safe and shrinks tumors. The goal is to find a better way to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Obstetrics and Gynecology Hospital of Zhejiang University

    RECRUITING

    Hangzhou, China

    Contact

  • Anyang Cancer Hospital

    RECRUITING

    Anyang, China

    Contact

  • Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College

    RECRUITING

    Beijing, China

    Contact

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, China

    Contact

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, China

    Contact

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, China

    Contact

  • Tianjin Cancer Hospital

    RECRUITING

    Tianjin, China

    Contact

Conditions

Explore the condition pages connected to this study.